Meeting
2012 Gastrointestinal Cancers Symposium
Efficacity and safety of panitumumab in mCRC patients: A post-AMM OMIT study.
Authors
Francoise Grude
OMIT Bretagne Pays de Loire, Angers, France
Francoise Grude , Jean François Ramée , Laurent Guivarch , Jean-Yves Douillard , Sophie Rochard , Olivier Dupuis , Chrystelle Grollier , Veronique Guerin-Meyer , Pierre Leynia , Marc Porneuf , Elodie Peguet , Jean Luc Raoul , Claude Bertrand , Philippe Deguiral , Laurent Derenne , Nacredine Achour , Bernadette Person , Jean-Philippe Metges , Marie-Annick Lebot , Christian Riche
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 608)
DOI
10.1200/jco.2012.30.4_suppl.608
Abstract #
608
Poster Bd #
E39
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2014 ASCO Annual Meeting
Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.
First Author: Albert Abad
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2011 Gastrointestinal Cancers Symposium
A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer.
First Author: Raymond Wadlow